Physician profile

Long Ly

New Orleans, LA

$1,878.76

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,791.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $592.15 2023
Ortho Dermatologics, A Division of Bausch Health US, LLC $376.64 2024 Siliq, Cabtreo, Altreno
Dermavant Sciences, INC. $249.17 2023 Vtama
Galderma Laboratories, L.P. $238.45 2023 Aklief, Twyneo, Oracea
Arcutis Biotherapeutics, INC. $209.43 2023-2024 Zoryve
Boehringer Ingelheim Pharmaceuticals, INC. $125.44 2023 Spevigo
Sun Pharmaceutical Industries INC. $40.81 2022
Genentech USA, INC. $24.83 2022
Kyowa Kirin, INC. $21.84 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Long Ly

$1,878.76

in general payments reported 2019-2025

Years
2022-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/11428910/long-ly

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.